Advaxis Schedules Annual General Meeting
Tuesday, June 1, 2010 | 1000 EDT
NASDAQ OMX 4 Times Square, NYC
March 17, 2010 10:05 AM Eastern Daylight Time
NORTH BRUNSWICK, N.J.--(EON: Enhanced Online News)--Advaxis, Inc., (OTCBB: ADXS), the live,
attenuated Listeria monocytogenes (Listeria) immunotherapy company, has scheduled its annual general meeting
for Tuesday, June 1, 2010 at 1000 EDT. The meeting will be hosted at Nasdaq OMX headquarters in New York
City. Formal invitations will be mailed over the coming few weeks.
“We are very proud to announce the rescheduling our annual general meeting and have it hosted at Nasdaq OMX
headquarters,” commented Advaxis Chairman/CEO Thomas A. Moore. “We look forward to meeting as many
shareholders as we can as we expect to report significant corporate progress on issues to be voted upon that will be
important to the future of the Company.”
About Advaxis, Inc.
Advaxis is a biotechnology company developing proprietary, live, attenuated Listeriamonocytogenes (Listeria)
vaccines that deliver engineered tumor antigens, which stimulate multiple, simultaneous immunological mechanisms to
fight cancer. Today, the Company has nine (9) distinct, cancer-fighting constructs in various stages of development,
directly and through strategic collaborations with such recognized sites of excellence as the City of Hope, the
Roswell Park Cancer Institute, the National Cancer Institute, the University of Pittsburgh and Cancer Research –
UK. Advaxis’ technology was developed by Dr. Yvonne Paterson, professor of microbiology at the University of
Pennsylvania and chairperson of Advaxis’ scientific advisory board.
Please visit the Company’s portals: advaxis.com | facebook | twitter | LinkedIn
Certain statements contained in this press release are forward-looking statements that involve risks and
uncertainties.The statements contained herein that are not purely historical are forward looking
statements within the meaning of Section 27A of t